Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients

One second-line patient achieved progression-free survival of 16.39 months and overall survival exceeding 20.7 months

RAMAT GAN, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing small molecule therapeutics targeting cancer and inflammatory diseases, today announced the presentation of final positive data from its Phase IIa clinical study of namodenoson in advanced pancreatic ductal adenocarcinoma at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

As previously announced, the study achieved its primary safety endpoint, demonstrating that oral namodenoson was well tolerated in patients with advanced pancreatic cancer who had received prior systemic therapies. Exploratory analyses also identified encouraging survival outcomes, supporting further clinical development in this challenging disease.

The single-center, open-label study enrolled 20 patients who received namodenoson at 25 mg twice daily. Fourteen patients received treatment in the third-line setting, three in the second-line setting, and three in the fourth-line setting.